Oncotech's corporate mission is to extend the survival and improve the quality of life of cancer patients. Oncotech provides innovative molecular oncology testing services to over one thousand hospitals throughout the United States and Europe to assist physicians in the care and management of their cancer patients. Oncotech is a market leader in the field of in vitro drug resistance and therapy selection testing, and performs innovative genomic research aimed at rapidly identifying new cancer diagnostics and therapeutics to improve the outcome of cancer patients. Oncotech was acquired by Exiqon A/S (now part of Qiagen) in 2008.